0300

Attorney Docket No.: 6236.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen alp

Serial No.: 10/003,846

Filed: December 4, 2001

Confirmation No.: 6436

& Group Art Unit: To be assigned

Examiner: To be assigned

For: Method of Identifying Compounds Capable of Acting as Agonists or Antagonists of G-

Protein Coupled Receptors

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement

MAR 0 7 2002

- 2. Form PTO-1449
- 3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on February 27, 2002.

Carol McFarlane-Fishberg

(name of person mailing paper)

(signature of person mailing paper)

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 6236.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 8 7 2002

In re Application of: Knudsen et al.

Application No.: 10/003,846

Filed: December 4, 2001

Examiner: To be assigned

Art Unit: To be assigned

Confirmation No.: 6436

For: Method of Identifying Compounds Capable of Acting as Agonists or Antagonists of

G-Protein Coupled Receptors

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- 1. WO 98/55635;
- 2. WO 99/55356;

- 3. WO 01/67106 A2;
- 4. U.S. Patent 5,891,646;
- 5. U.S. Patent 6,110,693; and
- 6. U.S. Patent 6,242,205 B1.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application. Therefore, no fee is due.

Respectfully submitted,

Date: February 27, 2002

Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

23650
PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)

U.S. DEPARTMENT ODCUMENCE PATENT AND PRADEMARK OFFICE

Atty. Docket No. 6236.200-US

Serial No. 10/003,846

INFORMATION DISCLOSURI STATEMENT BY APPLICAN

(Use several sheets if necessary)

MAR 8 7 2002

pplicant Knudsen et al.

Filing Date December 4, 2001

Group To be assigned

TATEST DOCUMENTS										
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	5,891,646	04/06/99	Barak et al.	435	7.2	06/05/97				
	6,110,693	08/29/00	Barak et al.	435	7.2	01/20/99				
	6,242,205 B1	06/05/01	Dohlman et al.	435	7.8	04/23/99				

FORFIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/55635	12/10/98	CIGIM				
	WO 99/55356	11/04/99	CPIW				
	WC 01/67106 A2	09/13/01	CHIM			1	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.